OSA management may be helpful in OSA but raises concerns about access to GLP-1s and abandoning lifestyle changes.
Will the weight reduction successes seen with use of glucagon-like peptide 1 agonists translate into improvement in obstructive sleep apnea ? Will those potential OSA benefits reduce the need for continuous positive airway pressure ? Experts are sharing the possible benefits while also emphasizing the important of lifestyle changes and pointing to concerns about access to GLP-1s.
"I think it's a game changer for helping people who are overweight or obese," said Samuel T. Kuna, MD, chief of sleep medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, in an interview."I think we're just starting out on a very exciting new era. We finally have quite effective treatments for this population.
Kuna said,"I don't think these agents eliminate the importance of behavioral modification, of changing diet, of reducing highly processed foods and maintaining a healthy lifestyle." He acknowledged, however, that behavioral endeavors have been in general disappointing with respect to patients' ability to achieve weight loss."These medicines really open up a new strategy to help patients do that," he added.
Despite the unanswered questions, the direction was unequivocally clear for Grunstein and colleagues:"Ultimately, the focus must shift away from mechanical therapy for obesity-related OSA toward weight loss, the latter which is likely to produce multiple health outcome improvements that are superior, including all-cause mortality.
Faiz commented,"The availability and consumption of ultra-processed foods can impact food intake and weight. Specifically, in a small study of 20 inpatient adults admitted to the NIH Clinical Center randomized to either ultra-processed or unprocessed diets for 14 days, increased caloric intake and weight gain were found in the ultra-processed cohort." In the, Faiz cited, meals were matched for calories, energy density, macronutrients, sugar, sodium, and fiber.
Sleep Apnoea Obesity Obese Sleep Disturbance Abnormal Sleep Pattern Sleep Disorder Somnipathy Weight Management Sleep Incretin Hormones Incretins Continuous Positive Airway Pressure CPAP Obstructive Sleep Apnea Obstructive Sleep Apnea Syndrome Obstructive Sleep Apnoea Obstructive Sleep Apnoea Syndrome Weight Loss Social Determinants Of Health SDOH
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1 Receptor Agonists Don't Raise Thyroid Cancer RiskA cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.
Read more »
EU Investigation Finds No Link Between GLP-1 Drugs and Suicide RiskHealth regulators in the European Union have concluded a nine-month investigation and found no evidence of a causative link between GLP-1 drugs and an increased risk of suicide or suicidal ideation. This should provide reassurance for individuals taking drugs like Ozempic to treat type 2 diabetes and/or obesity.
Read more »
GLP-1s May Increase Post-Endoscopy Aspiration Pneumonia RiskAlthough the overall incidence remains low, patients on GLP-1s have a 33% higher chance of aspiration pneumonia after endoscopic procedures, according to a new large population-based study.
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
Study Finds No Evidence of Thyroid Cancer Risk from GLP-1 AnaloguesA Swedish study of over 435,000 people has found no evidence to support concerns that long-term use of GLP-1 analogues, such as Wegovy and Ozempic, increases the risk of thyroid cancer.
Read more »